Arthritis in the Elderly: Is it Degenerative or Rheumatoid?

References

• Fuchs HA: Saturday conference: management of osteoarthritis. South Med J 80: 618–622, 1987.
   Web of Science ®Google Scholar
• Goldin RH, McAdam L, Louis JS, et al: Clinical and radiological survey of the incidence of osteoarthrosis among obese patients. Ann Rheum Dis 35: 349–353, 1976.
   Web of Science ®Google Scholar
• Scileppi KP: Bone and joint disease in the elderly. Med Clin North Am 67: 517–530, 1983.
   Web of Science ®Google Scholar
• Rodnan GP, Schumacher R, Zraifler NJ, eds: Primer on the Rheumatic Diseases, 8th ed. Atlanta, Arthritis Foundation, 1983, pp 38–48, 104–108, 174–179.
   Google Scholar
• Thumau GR: Rheumatoid arthritis. Clin Obstet Gynecol 26: 558–578, 1983.
   Google Scholar
• Krane SM, Simon LS: Rheumatoid arthritis: clinical features and pathogenetic mechanisms. Med Clin North Am 70: 263–284, 1986.
   PubMed Web of Science ®Google Scholar
• Hollingsworth JW, Saykaly RJ: Systemic complications of rheumatoid arthritis. Med Clin North Am 61: 217–228, 1977.
   PubMed Web of Science ®Google Scholar
• Bland JH: The reversibility of osteoarthritis: a review. Am J Med 74 (6A): 16–26, 1983.
   Web of Science ®Google Scholar
• Pinals RS: Approaches to rheumatoid arthritis and osteoarthritis: an overview. Am J Med 75 (4B): 2–9, 1983.
   Web of Science ®Google Scholar
• Mankin HJ, Thrasher AZ: Water content and binding in normal and osteoarthritic human cartilage. J Bone Joint Surg 57: 76–80, 1975.
   PubMed Web of Science ®Google Scholar
• Brandt KD, Palmoski MJ, Perricone E: Aggregation of cartilage proteoglycans: II. Evidence for the presence of a hyaluronate-binding region on proteoglycans from osteoarthritic cartilage. Arthritis Rheum 19: 1308–1314, 1976.
   Google Scholar
• Ali SY, Evans L: Enzymic degradation of cartilage in osteoarthritis. Fed Proc 32: 1494–1498, 1973.
   PubMedGoogle Scholar
• Gardner DL: The nature and causes of osteoarthritis. Br Med J 286: 418–424, 1983.
   PubMed Web of Science ®Google Scholar
• Juhl, JH: Paul and Juhl's Essentials of Roentgen Interpretation, 4th ed. Philadelphia, Harper Medical, 1981, pp 278–283, 291–292.
   Google Scholar
• Zraifler NJ: Immunopathology of joint inflammation in rheumatoid arthritis. Adv Immunol 16: 265–336, 1973.
   Google Scholar
• Harris ED, Jr.: Pathogenesis of rheumatoid arthritis. Clin Orthop 182: 14–23, 1984.
   PubMed Web of Science ®Google Scholar
• Smiley JD, Moore SE, Hoffman WL: Scientific overview of rheumatoid arthritis. Prog Clin Biol Res 106: 17–26, 1982.
   Google Scholar
• Simpson RW, McGinty L, Simon L, et al: Association of parvoviruses with rheumatoid arthritis of humans. Science 223: 1425–1428, 1984.
   PubMed Web of Science ®Google Scholar
• Stage DE, Mannik M: Rheumatoid factors in rheumatoid arthritis. Bull Rheum Dis 23: 720–725, 1973.
   Google Scholar
• Bloch KJ, Salvaggio JE: Use and interpretation of diagnostic immunologic laboratory tests. J Am Med Assoc 248: 2734–2758, 1982.
   Web of Science ®Google Scholar
• Reichel W, ed: Clinical Aspects of Aging. Baltimore, Williams and Wilkins Co., 1978, pp 261–269.
   Google Scholar
• Wright V: Treatment of severe arthritis. Br Med J 292: 431–432, 1988.
   Google Scholar
• Gabriel SE, Luthra HS. Rheumatoid arthritis: can the long-term outcome be altered? Mayo Clinc Proc 63: 58–68, 1988.
   PubMed Web of Science ®Google Scholar
• Maksymowych W, Russell AS: Antimalarials in rheumatology: efficacy and safety. Sem Arth Rh 16: 206–221, 1987.
   PubMed Web of Science ®Google Scholar
• Muirden KD: The use of chloroquine and D-penicillamine in the treatment of rheumatoid arthritis. Med J Aust 144: 32–34, 36–37, 1986.
   Web of Science ®Google Scholar
• Abruzzo JL: Auranofin: a new drug for rheumatoid arthritis. Ann Intern Med 105: 274–276, 1986.
   Web of Science ®Google Scholar
• Hochberg MC: Auranofin or D-penicillamine in the treatment of rheumatoid arthritis. Ann Intern Med 105: 528–535, 1986.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Orth RW, Catherwood BD, et al: Measures of bone loss in rheumatoid arthritis. Arch Intern Med 146: 701–704, 1986.
   Google Scholar
• Mason M, Currey HL, Barnes CG, et al Azathioprine in rheumatoid arthritis. Brit Med J 1: 420–422, 1969.
   PubMed Web of Science ®Google Scholar
• Csuka M, Carrera GF, McCarty DJ: Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine: a follow-up study. J Am Med Assoc 255: 2315–2319, 1986.
   PubMed Web of Science ®Google Scholar
• Cooperating Clinics Committee of the American Rheumatoid Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. N Engl J Med 283: 883–889, 1970.
   Web of Science ®Google Scholar
• Weinblatt ME, Coblyn JS, Fox DA, et al: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312: 818–822, 1985.
   PubMed Web of Science ®Google Scholar
• Klippel JH, Decker JL. Methotrexate in rheumatoid arthritis. N Engl J Med 312: 853–854, 1985.
   PubMed Web of Science ®Google Scholar
• Nordstrom DM, West SG, Anderson PA, et al: Pulse methotrexate therapy in rheumatoid arthritis: a controlled perspective roentgenographic study. Ann Intern Med 107: 797–801, 1987.
   PubMed Web of Science ®Google Scholar
• Tugwell P, Bennett K, Gent M: Methotrexate in rheumatoid arthritis: indications, contraindications, efficacy, and safety. Ann Intern Med 107: 358–366, 1987.
   Web of Science ®Google Scholar
• Health and Public Policy Committee, American College of Physicians: Methotrexate in rheumatoid arthritis. Ann Intern Med 107: 418–419, 1987.
   Web of Science ®Google Scholar
• Ytterberg SR, Knodell RG, Mahowald ML: Lack of methotrexate hepatotoxicity in rheumatoid arthritis. Contemporary Gastro 1: 21–26, 1988.
   Google Scholar
• Huskisson EC, Adams JG: An overview of the current state of levamisole in the treatment of rheumatoid diseases. Drugs 19: 100–104, 1980.
   Google Scholar
• Bunch TW, O'Duffy JO: Disease-modifying drugs for progressive rheumatoid arthritis. Mayo Clin Proc 55: 161–179, 1980.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Jabiz W, Michalek A, et al: Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 106: 497–502, 1987.
   PubMed Web of Science ®Google Scholar
• Martin MF, Surall KE, McKenna F, et al: Captopril: a potential new treatment for rheumatoid arthritis? Lancet 1: 1325–1328, 1984.
   PubMed Web of Science ®Google Scholar
• Mant MJ, Akabutu JJ, Herbert FA: Lithium carbonate therapy in severe Felty's syndrome: benefits, toxicity, and granulocyte function. Arch Intern Med 146: 277–280, 1986.
   Google Scholar
• Strober S, Tanay A, Field E, et al: Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis: a double-blind, randomized trial. Ann Intern Med 102: 441–449, 1985.
   PubMed Web of Science ®Google Scholar
• Trentham DE, Weinblatt ME, Austen KF: Total lymphoid irradiation in tertiary care for rheumatoid arthritis. Ann Intern Med 102: 544–545, 1985.
   Web of Science ®Google Scholar
• Dugowson CE, Gilliland BC: Management of rheumatoid arthritis. D M 32: 1–74, 1986.
   Web of Science ®Google Scholar
• St. Clair EW, Polisson RP: Therapeutic approaches to the treatment of rheumatoid disease. Med Clin North Am 70: 285–304, 1986.
   Web of Science ®Google Scholar
• Baker DG, Rabinowitz JL: Current concepts in the treatment of rheumatoid arthritis. J Clin Pharmacol 26: 2–21, 1986.
   Web of Science ®Google Scholar
• Wilder RL: Treatment of the patient with rheumatoid arthritis refractory to standard therapy. J Am Med Assoc 259: 2446–2449, 1988.
   PubMed Web of Science ®Google Scholar